1
TITLE: Subgroup analyses results of the PETACC8 phase III trial comparing adjuvant FOLFOX4 with or without cetuximab (CTX) in resected stage III colon cancer (CC).
AUTHORS: Julien Taieb; Josep Tabernero; Enrico Mini; Fabien Subtil; Gunnar Folprecht; Jean Luc Van Laethem; Joseph Thaler; John A Bridgewater; Evaristo Sanches; Lone Petersen; Laurence Collette; Eric Van Cutsem; Karine Le Malicot; Philippe Rougier; Ramon Salazar; Laurent Bedenne; Jean Francois Emile; Pierre Laurent Puig; Come Lepage;
PUBLISHED: 2013, SOURCE: 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) in JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 31, ISSUE: 15
INDEXED IN: WOS
2
TITLE: ADJUVANT FOLFOX4+/- CETUXIMAB IN KRAS WILD-TYPE PATIENTS WITH RESECTED STAGE III COLON CANCER RESULTS FROM THE PETACC8 INTERGROUP TRIAL
AUTHORS: Julien Taieb; Josep Tabernero; Enrico Mini; Fabien Subtil; Gunnar Folprecht; Jean Luc Van Laethem; Josef Thaler; John Bridgewater; Evaristo Sanches; Lone Norgard Petersen; Philippe Rougier; Laurence Collette; Michel Praet; Cecile Girault; Martina Schneider; Pierre Squifflet; Pierre Laurent Puig; Eric Van Cutsem; Laurent Bedenne; Come Lepage;
PUBLISHED: 2012, SOURCE: 14th World Congress on Gastrointestinal Cancer of the European-Society-for-Medical-Oncology (ESMO) in ANNALS OF ONCOLOGY, VOLUME: 23
INDEXED IN: WOS